Literature DB >> 24371674

Unexpected long-term survival in a BRCA2 patient with metastatic carcinosarcoma associated with tamoxifen.

Ana Clara1, Isabel Fonseca2, Ana Francisca1, António Bettencourt1, Fátima Vaz1.   

Abstract

► This report concerns a long survival of a BRCA2 patient with a relapsing uterine carcinosarcoma. ► Rarity of long survivorship in relapsing carcinosarcoma is confirmed by literature review. ► BRCA2 status plus platinum-hypersensitivity as contributors for the favorable outcome, even if carcinosarcoma doesn't belong to the BRCA1/2 phenotype.

Entities:  

Keywords:  BRCA1/2 mutations; Carcinosarcoma; Platinum-hypersensitivity

Year:  2013        PMID： 24371674      PMCID： PMC3862302          DOI： 10.1016/j.gynor.2012.12.010

Source DB:  PubMed          Journal:  Gynecol Oncol Case Rep        ISSN： 2211-338X


  10 in total

1.  Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity.

Authors:  H Fujii; M Yoshida; Z X Gong; T Matsumoto; Y Hamano; M Fukunaga; R H Hruban; E Gabrielson; T Shirai
Journal:  Cancer Res       Date:  2000-01-01       Impact factor: 12.701

2.  Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

Authors:  Panagiotis A Konstantinopoulos; Dimitrios Spentzos; Beth Y Karlan; Toshiyasu Taniguchi; Elena Fountzilas; Nancy Francoeur; Douglas A Levine; Stephen A Cannistra
Journal:  J Clin Oncol       Date:  2010-06-14       Impact factor: 44.544

3.  The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study.

Authors:  Mario E Beiner; Amy Finch; Barry Rosen; Jan Lubinski; Pal Moller; Parviz Ghadirian; Henry T Lynch; Eitan Friedman; Ping Sun; Steven A Narod
Journal:  Gynecol Oncol       Date:  2006-09-08       Impact factor: 5.482

4.  Primary peritoneal carcinosarcoma (malignant mixed mullerian tumor): Report of a case with five-year disease free survival after surgery and chemoradiation and a review of literature.

Authors:  Ma-Lee Ko; Cherng-Jye Jeng; Shih-Hung Huang; Jenta Shen; Chii-Ruey Tzeng; Su-Chee Chen
Journal:  Acta Oncol       Date:  2005       Impact factor: 4.089

5.  Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study.

Authors:  J P Curtin; J A Blessing; J T Soper; K DeGeest
Journal:  Gynecol Oncol       Date:  2001-11       Impact factor: 5.482

6.  Malignant mixed mullerian tumors of the ovary. An analysis of two long-term survivors.

Authors:  K K Dass; C V Biscotti; K Webster; J P Saxton
Journal:  Am J Clin Oncol       Date:  1993-08       Impact factor: 2.339

7.  Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer.

Authors:  Rochelle E Curtis; D Michal Freedman; Mark E Sherman; Joseph F Fraumeni
Journal:  J Natl Cancer Inst       Date:  2004-01-07       Impact factor: 13.506

8.  Cure of metastatic uterine carcinosarcoma to lungs: a case report.

Authors:  A Shamseddine; A Taher; Y Abou-Mourad; M Seoud; A Khalil
Journal:  Int J Gynecol Cancer       Date:  2003 Jan-Feb       Impact factor: 3.437

9.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

Authors:  Marco Gerlinger; Andrew J Rowan; Stuart Horswell; James Larkin; David Endesfelder; Eva Gronroos; Pierre Martinez; Nicholas Matthews; Aengus Stewart; Charles Swanton; M Math; Patrick Tarpey; Ignacio Varela; Benjamin Phillimore; Sharmin Begum; Neil Q McDonald; Adam Butler; David Jones; Keiran Raine; Calli Latimer; Claudio R Santos; Mahrokh Nohadani; Aron C Eklund; Bradley Spencer-Dene; Graham Clark; Lisa Pickering; Gordon Stamp; Martin Gore; Zoltan Szallasi; Julian Downward; P Andrew Futreal
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

10.  The impact of multi-modal therapy on survival for uterine carcinosarcomas.

Authors:  Jesus Gonzalez Bosquet; Shelby A Terstriep; William A Cliby; Monica Brown-Jones; Judith S Kaur; Karl C Podratz; Gary L Keeney
Journal:  Gynecol Oncol       Date:  2009-11-05       Impact factor: 5.304
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.